Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10093009 | 0.93 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL15142718 | 0.90 | CNR2 (0.66) | CNR1CNR2 | |
| SCHEMBL10093007 | 0.90 | CNR2 (0.77) | CNR1CNR2 | |
| SCHEMBL10093008 | 0.90 | CNR2 (0.64) | CNR1CNR2 | |
| SCHEMBL670365 | 0.87 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL670149 | 0.86 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL15142732 | 0.85 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL10093006 | 0.85 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL15142731 | 0.84 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL10093012 | 0.82 | CNR1 (0.67) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2606032-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | University Of Washington Through Its Center For Commercialization (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | CNR1 2351/4885CNR2 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.